Quince Therapeutics, a late-stage biotechnology company, announced safety data from its Phase 3 ATTeST clinical trial at the 53rd Child Neurology Society Annual Meeting. The trial assessed treatment-emergent adverse events (TEAEs) in Ataxia-Telangiectasia (A-T) patients treated with EryDex (intra-erythrocyte dexamethasone sodium phosphate) for one year versus a placebo.